Alprazolam detailed information

Jump to: navigation, search
Alprazolam detailed information
Alprazolam.svg
Alprazolam3d.png
Clinical data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability80-90%
MetabolismHepatic, via Cytochrome P450 3A4
Elimination half-lifeImmediate release: 11.2 hours;[1] Extended release: 10.7-15.8 hours[2]
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC17H13ClN4
Molar mass308.765

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]


Overview

Alprazolam, also known under the trade names Xanax and Niravam, is a short-acting drug of the benzodiazepine class used to treat moderate to severe anxiety disorders, panic attacks, and as an adjunctive treatment for anxiety associated with clinical depression. It is also available in an extended release form, Xanax XR. Both forms are now available generically.

History

"[The public often] underestimate the extent to which certain disorders affect the general populace. When you treat them, it can make a tremendous amount of difference in their lives." (David Sheehan, first discovered alprazolam's efficacy in treating panic disorder.[3])

Alprazolam was first synthesized by Upjohn (now a part of Pfizer). Its patent (#3,987,052)[4] was filed on October 29, 1969, granted on October 19, 1976 and expired in September 1993. It was released in 1981.[5][6] The first indication for which alprazolam was approved was panic disorder. Upjohn took this direction at the behest of a young psychiatrist David Sheehan. Sheehan's suggestion was to use the confusion DSM-III created in the classification of anxiety disorders (a distinction had just been made in DSM-III between generalized anxiety disorder (GAD) and panic disorder). Panic disorder was, at that point, perceived to be rare and treatable only with tricyclic antidepressants; benzodiazepines were thought to be ineffective. However, from his clinical experience, Sheehan knew panic disorder to be both widespread among the populace and well responding to benzodiazepines. He suggested to Upjohn that marketing alprazolam for panic disorder will both cover new diagnostic territory and stress the unique potency of this drug. Sheehan describes that the first group of patients treated by alprazolam was so impressed by its action that they knew outright—this drug was going to be a hit. A few of the patients pooled their money and bought the Upjohn’s stock. Several months later, when alprazolam was approved by the FDA, they sold out and made a profit.[7]

Pharmacology

Alprazolam is a triazolobenzodiazepine,[8] that is, a benzodiazepine with a triazolo-ring attached to its structure. Benzodiazepines produce a variety of effects by modulating the GABAA subtype of the GABA receptor, the most prolific inhibitory receptor within the brain. The GABAA receptor is made up from 5 subunits out of a possible 19, and GABAA receptors made up of different combinations of subunits have different properties, different locations within the brain and importantly, different activities in regards to benzodiazepines.

In order for GABAA receptors to be sensitive to the action of benzodiazepines they need to contain an α and a γ subunit, where the benzodiazepine binds. Once bound, the benzodiazepine locks the GABAA receptor into a conformation where the neurotransmitter GABA has much higher affinity for the GABAA receptor, increasing the frequency of opening of the associated Chloride ion channel and hyperpolarising the membrane. This potentiates the inhibitory effect of the available GABA leading to sedatory and anxiolytic effects. As mentioned, different benzodiazepines can have different affinities for GABAA receptors made up of different collection of subunits. For instance, benzodiazepines with high activity at the α1 are associated with sedation whereas those with higher affinity for GABAA receptors containing α2 and/or α3 subunits have greater anxiolytic activity.

The binding site for benzodiazepines is distinct from the binding site for barbiturates and GABA on the GABA receptor.

There is some evidence for antidepressant treatment of clinical depression in out patient settings, evidence for inpatients is lacking;[9] other benzodiazepines are not known to have antidepressant activity.

Pharmacokinetics

Alprazolam is readily absorbed from the gastrointestinal tract. The peak plasma concentration is achieved in 1-2 hours. Most of the drug is bound to plasma protein, mainly serum albumin. Alprazolam is hydroxylated in the liver to α-hydroxyalprazolam, which is also pharmacologically active. This and other metabolites are later excreted in urine as glucuronides. Some of the drug is also excreted in unchanged form.

Indications

alprazolam 2mg tablet bottle

The main medical uses for alprazolam include:

  • Alprazolam is FDA-approved for the short term treatment (up to 8 weeks) of panic disorder, with or without agoraphobia. Alprazolam is very effective in preventing moderate to severe anxiety, essential tremor, panic attacks and other types of convulsive behaviors. Physicians who elect to prescribe alprazolam for longer than 8 weeks should be aware that continued efficacy has not been systematically demonstrated beyond 8 weeks use as tolerance to alprazolam's effects may occur after 8 weeks and necessitate discontinuation or physician-directed dose escalation.[10] However, long-term maintenance therapy on alprazolam is not unheard-of in the medical community, and, if a genuine therapeutic need exists, benefits must be weighed against risks.
  • Alprazolam is recommended for the short-term treatment (2-4 weeks) of severe acute anxiety. Alprazolam should only very rarely be used for longer periods of time -- the body becomes rapidly tolerant to the drug's effects, which may translate to decreased efficacy.[11][12] Decreased efficacy can lead to dose escalation, and the use of high doses puts the patient at higher risk for withdrawal if the drug is discontinued suddenly.
  • However, in 1992 Romach and colleagues reported that dose escalation was not a characteristic of long-term alprazolam users, and the majority of patients indicated that alprazolam continued to be effective.[13] A 2003 study did not support the hypothesis that long-term use of benzodiazepines frequently results in notable dose escalation.[14]In a 1-year follow-up study of patients with panic disorder continuing treatment with clonazepam, 90% maintained a positive response without developing significant tolerance. In a 2.5-year follow-up study of alprazolam therapy, little evidence of tolerance emerged.[15]

Availability

Holographic advertisement for Xanax, 1989.

Xanax is the main and most commonly known brand name for Alprazolam. There is a large variety of generic brand names for Alprazolam in use throughout the world. In English-speaking countries, Alprazolam is sold under the following brand names: Aloram, Alprax, Alprox, Alzam, Anxirid, Apo-Alpraz, Azor, Calmax, Frontal, Frontin, Gerax, Helex, Kalma, Kinax, Neurol, Novo-Alprazol, Nu-Alpraz, Restyl, Trankimazin, Xanax, Xanor, Zopax, Trika. It is also commonly known as "Totem Poles" or "Ladders" or "Bars" or "Yellow Buses" or "French Fries" when laced, when sold or used illegally.

Packaging

Xanax DOJ.jpg

Imprints vary depending on drug manufacturer. The imprints above refer to the name-brand design in the United States and other first world countries,[16] however, every variety of alprazolam is generically available and thus individual pill design is left up to the manufacturer.

Side effects

Side effects of alprazolam may occur in patients and are more likely the higher the dosage taken. If signs of an allergic reaction occur such as hives, difficulty breathing, swelling of face, lips, tongue or throat occur medical attention should be sought immediately. Medical attention should also be sought immediately if signs of jaundice appear such as yellowing of the skin or eyes. Other side effects which may occur are as follows:[17][18][19][20]

Physical dependence and withdrawal

There is a consensus among psychiatrists today that alprazolam and other benzodiazepines cause withdrawal symptoms after long-term treatment and discontinuation should be done gradually over a period of months (or even up to a year) to avoid serious withdrawal symptoms such as agitation, panic attacks, rebound anxiety, muscle cramps and seizures. Some patients may benefit from a substitution with diazepam (Valium) or chlordiazepoxide (Librium) as these drugs remain in the bloodstream longer and therefore have less potential for abuse and dependence.

Patients treated with alprazolam or other benzodiazepines for generalized anxiety disorder were found (when abruptly discontinuing their medication) to experience withdrawal symptoms such as a worsening of anxiety, as well as the development of physical withdrawal symptoms.[21]

Patients taking a dosing regimen larger than 4 mg per day have an increased potential for dependence. This medication may cause withdrawal symptoms, which in some cases have been known to cause seizures. The discontinuation of this medication may also cause a reaction called rebound anxiety. Other withdrawal effects reported from discontinuing alprazolam therapy include homicidal ideation, rage reactions, hyperalertness, increased nightmares, and intrusive thoughts.[22]

After 8 - 9 weeks of alprazolam taken at a fixed prescribed dose, the following symptoms have been found to occur during abrupt discontinuation; dysphoric mood, fatigue, low energy, confusion, and elevated systolic blood pressure, severe anxiety.[23]

When a patient discontinues use, they may experience the symptoms they had before taking medication. Symptoms may also be accompanied by other reactions including changes in mood, anxiety, or sleep. Rebound anxiety is usually a result of abrupt discontinuation of this medication; patients who taper off are less likely to experience these symptoms.

Physical dependence is the major limiting factor against long-term use of alprazolam and other benzodiazepines.

Factors which determine the severity of the benzodiazepine withdrawal syndrome experienced during dose reduction of alprazolam include:[24]

  • dosage
  • length of use
  • frequency of dosing
  • method of withdrawal[25]
  • personality characteristics of the individual
  • previous use of cross dependent/cross tolerant drugs (alcohol or other sedative hypnotic drugs)
  • current use of cross dependent/cross tolerant drugs (alcohol or other sedative hypnotic drugs)
  • Use of short-acting high potency benzodiazepines for example alprazolam or lorazepam

Alprazolam has an exceptional history insofar soon after its introduction a large number of case reports were published in the medical literature of severe withdrawal symptoms related case reports of withdrawal psychoses, seizures and intense rebound anxiety upon discontinuation of alprazolam. In the United States a survey of physicians showed that 84% of physicians reported alprazolam as being extremely problematic in terms of the severity and prolonged nature of the benzodiazepine withdrawal syndrome after discontinuation.

However, in 1993 the New England Journal of Medicine reported there is no reliable evidence to support the existence of a persistent benzodiazepine withdrawal syndrome, and this syndrome has been described only in anecdotal reports, with patients typically reporting "withdrawal" symptoms not present during or before benzodiazepine treatment that persist for many months or years after treatment is stopped. Experimental neuropharmacologic studies document that all the side effects of benzodiazepines, whether behavioral or neurochemical, disappear within several days or weeks after the drug is eliminated. The weight of evidence indicates that any new symptoms that persist for more than two months after the last dose of a benzodiazepine either are part of the premorbid condition or have appeared by coincidence or as a consequence of the natural history of the underlying illness.[26]

The benzodiazepines diazepam(Valium) and oxazepam(Seresta) were found to produce less severe withdrawal symptoms than alprazolam(Xanax) or lorazepam(Temesta/Ativan).[24]

Alprazolam should never be abruptly discontinued if taken regularly for any length of time because severe withdrawal symptoms may occur. Severe psychosis and seizures have been reported in the medical literature from abrupt alprazolam withdrawal,[27][28] and one death occurred from withdrawal-related seizures after gradual dose reduction.[28]

Contraindications

Use of alprazolam should be avoided, or carefully monitored by medical professionals, in individuals with the following conditions:[29][30]

Overdose

Overdoses can be mild to severe depending on how much of the drug is taken and if any other depressants have been taken. Xanax overdose reflect the central nervous system depression of the brain and may include one or more of the following symptoms:

About 50% of the cases of death involving alprazolam were attributed to combined drug toxicity of alprazolam and another drug, most often cocaine and methadone. Only 1% of such deaths was attributed to alprazolam alone.[32]

Pregnancy

Women who are pregnant or are planning on becoming pregnant should avoid starting alprazolam.[33] If one is currently planning to become pregnant, one should discuss this and all medicines with their obstetrician or other doctor.

Teratogenicity classification

Marked Pregnancy Category D by the U.S. FDA.

Effects on the fetus

It should be considered that the child born of a mother who is receiving benzodiazepines may be at risk of developing withdrawal symptoms from the drug during the postnatal period. Also, neonatal flaccidity and respiratory problems have been reported in children born of mothers who have been receiving benzodiazepines.[34]

Labor and delivery

Alprazolam has no established use in labor or delivery.

Nursing mothers (neonates)

Benzodiazepines, including alprazolam are known to be excreted in human milk.[35] Chronic administration of diazepam to nursing mothers has been reported to cause their infants to become lethargic and to lose weight.[36] As a general rule, nursing should not be undertaken by mothers who use alprazolam.

Geriatric use

Elderly individuals should be cautious in the use of alprazolam due to the possibility of increased susceptibility to side effects, especially loss of coordination and drowsiness.[37]

Food and drug interactions

Eating grapefruits or drinking grapefruit juice while using alprazolam increases blood concentrations by inhibiting the intestinal metabolism.[38]

In fact, any drug that inhibits CYP3A4, for which alprazolam is a substrate, will increase serum concentrations of alprazolam significantly if administered prior or concurrently. Tagamet (cimetidine) is a widely used H2 blocker antacid that inhibits numerous cytochrome P450 enzymes.

Oral contraceptive pills reduce the clearance of alprazolam, which may lead to increased plasma levels of alprazolam and accumulation.[39]

Special precautions

Like all central nervous system depressants, including alcohol, alprazolam in doses of 0.5 mg and above can cause significant deterioration in alertness, combined with increased feelings of sleepiness.[40] People driving or conducting activities which require vigilance should exercise caution in using alprazolam or any other depressant.

Recreational use

Sandoz generic 2mg alprazolam tablets

Alprazolam, like all benzodiazepines, has the potential for abuse. Although it is not manufactured illegally, and its misuse and abuse is dwarfed by benzodiazepines like flunitrazepam, nimetazepam, and temazepam, it is still often diverted to the black market, particularily in the United States where alprazolam is the most widely prescribed benzodiazepine. The state of relaxation, anxiolysis, and disinhibition induced by benzodiazepines is the main reason for their illicit use.

Most alprazolam abusers "are generally but not entirely limited to patients involved in a polydrug use pattern"[41] In fact, according to an April 2004 report by the U.S. SAMHSA, "over three-quarters (78%) of benzodiazepine-related (emergency room) visits involved 2 or more drugs."[42].

Injection of alprazolam is considered especially dangerous by medical professionals[43] because, when crushed in water it will not fully dissolve (40µg/ml of H2O at pH 7, and 12 mg/mL at pH 1.2 per 1mg of alprazolam[44]), potentially causing severe damage to arteries if not filtered properly. While it is somewhat soluble in alcohol, the combination of the two, particularly when injected, has the potential to cause a serious, and potentially fatal overdose. Alprazolam may also be insufflated; clinical testing indicates potent activity through insufflation yet some sources indicate sublingual activity is greater.[45]

Alprazolam is sometimes used with other recreational drugs to relieve the panic or distress of dysphoric reactions to psychedelics such as LSD and also to promote sleep in the "come-down" period following use of recreational drugs with stimulant or insomniac properties (such as LSD, cocaine, amphetamines, DXM, and MDMA along with the related amphetamines). It is also often used in conjunction with marijuana or heroin to potentiate the relaxing effect. As with all drugs, taking it on an empty stomach ensures the most powerful effect. Some anti-drug sourcesTemplate:Weasel word provide disinformation by stating that alprazolam is more potent when taken with cola--the acidic nature of colas actually decreases its absorption--acidity decreases the absorption of most orally taken pharmaceuticals.

Patients at a high risk for abuse and dependence

At a particularly high risk for misuse, abuse, and dependence are polydrug abusers (someone who already uses at least one substance in a recreational context). However, the following can also indicate potential problems in the future:

  • Patients with a history of alcohol or drug abuse and/or dependence
  • Patients with severe personality disorders or emotional instability
  • Patients with chronic pain or other physical disorders

Patients from the aforementioned group should be monitored very closely during therapy for signs of abuse and development of dependence because it may cause addiction. Discontinue therapy if any of these signs are noted. Long-term therapy in these patients is not recommended, unless the net benefit to the patient outweighs the net risk.

A large scale nation wide USA government study conducted by samhsa found that benzodiazepines in the USA are the most frequently abused pharmaceutical with 35% of drug related visits to the Emergency Department involved benzodiazepines. Benzodiazepines are more commonly abused than opiate pharmaceuticals which accounted for 32% of visits to the emergency department. No other pharmaceutical is more commonly abused than benzodiazepines. Males abuse benzodiazepines as commonly as women. Of drugs used in attempted suicide benzodiazepines are the most commonly used pharmaceutical drug with 26% of attempted suicides involving benzodiazepines. The most commonly abused benzodiazepine is however, alprazolam. Clonazepam is the 2nd most abused benzodiazepine. Lorazepam is the third most commonly abused benzodiazepine and diazepam the 4th most commonly abused benzodiazepine in the USA. Alprazolam is also commonly abused in combination with alcohol.[46]

Legal status

In the United States, alprazolam is a prescription drug and is assigned to Schedule IV of the Controlled Substances Act by the Drug Enforcement Administration. Under the UK drug misuse classification system benzodiazepines are class C drugs.[47] Internationally, alprazolam is included under the United Nations Convention on Psychotropic Substances as Schedule IV.[48]

References

  1. Xanax (Alprazolam) clinical pharmacology - prescription drugs and medications at RxList
  2. Xanax XR (Alprazolam) clinical pharmacology - prescription drugs and medications at RxList
  3. Research.Online - University of South Florida's Research Guide
  4. Patent 3,987,052
  5. Xanax junkies - News - The Phoenix
  6. 1981 American Journal of Psychiatry contains advertisements for Xanax as an available drug.
  7. Healy, David (2000). The Psychopharmacologists, Vol. III: Interviews. London: Arnold. pp. 479–504. ISBN 0-340-761105.
  8. J Med. Chem. Vol. 14, p. 1078-1081 (1971) DOI: 10.1021/jm00293a015
  9. Alprazolam as an antidepressant. [J Clin Psychiatry. 1988] - PubMed Result
  10. FDA (23rd). "FDA APPROVED LABELING FOR XANAX XR" (pdf). Federal Drug Administration. p. 4. The longer-term efficacy of XANAX XR has not been systematically evaluated. Thus, the physician who elects to use this drug for periods longer than 8 weeks should periodically reassess the usefulness of the drug for the individual patient. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Unknown parameter |month= ignored (help); Check date values in: |date=, |year= / |date= mismatch (help)
  11. NetDoctor (1). "Xanax" (PDF). netdoctor.co.uk. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Unknown parameter |month= ignored (help); Check date values in: |date=, |year= / |date= mismatch (help)
  12. The British National Formulary (2007). "Alprazolam". BNF. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  13. Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL, Sellers EM (1992). "Characteristics of long-term alprazolam users in the community". J Clin Psychopharmacol. 12 (5): 316–21. doi:10.1097/00004714-199210000-00004. PMID 1479048.
  14. Soumerai SB, Simoni-Wastila L, Singer C; et al. (2003). "Lack of relationship between long-term use of benzodiazepines and escalation to high dosages". Psychiatr Serv. 54 (7): 1006–11. doi:10.1176/appi.ps.54.7.1006. PMID 12851438.
  15. Pollack MH (1990). "Long-term management of panic disorder". J Clin Psychiatry. 51 Suppl: 11–3, discussion 50–3. PMID 1970813.
  16. BENZODIAZEPINE Imprints - Drugs.com
  17. "Complete Alprazolam information from Drugs.com". drugs.com. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  18. "ALPRAZOLAM - ORAL (Xanax) side effects, medical uses, and drug interactions". medicinenet.com. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  19. "Alprazolam – Complete medical information regarding this treatment of anxiety disorders on MedicineNet.com". medicinenet.com. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  20. "alprazolam Side Effects, Interactions and Information - Drugs.com". drugs.com. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  21. Chouinard G (1983). "New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines". Prog Neuropsychopharmacol Biol Psychiatry. 7 (4–6): 669–73. doi:10.1016/0278-5846(83)90043-X. PMID 6141609. Unknown parameter |coauthors= ignored (help)
  22. Risse SC (1990). "Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder". The Journal of clinical psychiatry. 51 (5): 206–9. PMID 2335496. Unknown parameter |coauthors= ignored (help)
  23. Uhlenhuth EH (2006). "Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs". J Clin Psychopharmacol. 26 (5): 519–23. PMID 16974197. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
  24. 24.0 24.1 Wolf B (1991). "Physical dependence on benzodiazepines: differences within the class". Drug and alcohol dependence. 29 (2): 153–6. doi:10.1016/0376-8716(91)90044-Y. PMID 1686752. Unknown parameter |coauthors= ignored (help)
  25. The Ashton Manual - Benzodiazepines: How They Work and How to Withdraw by professor Heather Ashton
  26. Shader RI, Greenblatt DJ (1993). "Use of benzodiazepines in anxiety disorders". N. Engl. J. Med. 328 (19): 1398–405. doi:10.1056/NEJM199305133281907. PMID 8292115.
  27. Levy AB (1984). "Delirium and seizures due to abrupt alprazolam withdrawal: case report". J Clin Psychiatry. 45 (1): 38–9. PMID 6141159.
  28. 28.0 28.1 Haque W, Watson DJ, Bryant SG (1990). "Death following suspected alprazolam withdrawal seizures: a case report". Tex Med. 86 (1): 44–7. PMID 2300914.
  29. "Alprazolam". British National Formulary. 2007. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  30. mentalhealth.com (2007). "Alprazolam". Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  31. Hori A. (1998). "Pharmacotherapy for personality disorders". Psychiatry and clinical neurosciences. 52 (1): 13–9. doi:10.1111/j.1440-1819.1998.tb00967.x. PMID 9682928. Unknown parameter |month= ignored (help)
  32. Wolf BC, Lavezzi WA, Sullivan LM, Middleberg RA, Flannagan LM (2005). "Alprazolam-related deaths in Palm Beach County". Am J Forensic Med Pathol. 26 (1): 24–7. PMID 15725773.
  33. Xanax (Alprazolam) drug warnings and precautions - prescription drugs and medications at RxList
  34. García-Algar O (2007). "Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis". Clinical toxicology (Philadelphia, Pa.). 45 (3): 295–8. PMID 17453885. Unknown parameter |coauthors= ignored (help)
  35. Oo CY (1995). "Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk". British journal of clinical pharmacology. 40 (3): 231–6. PMID 8527284. Unknown parameter |month= ignored (help); Unknown parameter |coauthors= ignored (help)
  36. [1][2]
  37. ALPRAZOLAM - ORAL (Xanax) side effects, medical uses, and drug interactions
  38. http://www.fhma.com/grapefruit.htm
  39. Back DJ (1990). "Pharmacokinetic drug interactions with oral contraceptives". Clin Pharmacokinet. 18 (6): 472–84. PMID 2191822. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
  40. Kozená L (1995). "Vigilance impairment after a single dose of benzodiazepines". Psychopharmacology (Berl). 119 (1): 39–45. PMID 7675948. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
  41. Landry, J. Understanding Drugs of Abuse: The Processes of Addiction, 1994.
  42. 7393.14.02 DAWN tdr_Benzo
  43. Eric C (2006). "MR Findings of Alprazolam Injection into the Femoral Artery with Microembolization and Rhabdomyolysis" (pdf). Radiology Case Reports. 1 (3). Unknown parameter |coauthors= ignored (help)
  44. DrugBank: DB00404 (Alprazolam)
  45. PanthraX-Nation - Get Addicted
  46. United States Government (2004). "Drug Abuse Warning Network, 2004: National Estimates of Drug-Related Emergency Department Visits". Substance Abuse and Mental Health Services Administration. Unknown parameter |accessdaymonth= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Unknown parameter |coauthors= ignored (help)
  47. Misuse of Drugs Act 1971 (c. 38) - Statute Law Database
  48. List of psychotropic substances under international control

External links

bg:Алпразолам de:Alprazolam fa:آلپرازولام gl:Alprazolam it:Alprazolam hu:Alprazolám nl:Alprazolam no:Alprazolam fi:Alpratsolaami sv:Alprazolam



Linked-in.jpg